Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Summary

The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in patients with Proliferative Diabetic Retinopathy (PDR).

Timeline

Start

2012-12-11

Primary completion

2016-11-30

Completion

2017-12-05

Outcome

Met primary endpoint

registry analysis (other test); Ranibizumab Mono vs PRP Mono; p = 0.0344; Least Squares Mean Difference -2.8 (95% CI -5.4 to -0.2); ANCOVA NCT01594281 ↗

Drugs

Indications